688321 微芯生物
已收盘 05-08 15:00:00
资讯
新帖
简况
2025年化学制药行业现状分析：优化工作设计
报告大厅 · 02:46
2025年化学制药行业现状分析：优化工作设计
【机构调研记录】凯石基金调研ST华通、微芯生物
证券之星 · 00:04
【机构调研记录】凯石基金调研ST华通、微芯生物
【机构调研记录】先锋基金调研微芯生物
证券之星 · 00:04
【机构调研记录】先锋基金调研微芯生物
微芯生物：西格列他钠营收大增 研发管线持续推进
财通证券 · 05-07 16:00
微芯生物：西格列他钠营收大增 研发管线持续推进
微芯生物：2024年西格列他钠（双洛平）糖尿病适应症成功原价续约医保谈判
证券之星 · 05-07 10:12
微芯生物：2024年西格列他钠（双洛平）糖尿病适应症成功原价续约医保谈判
微芯生物：此处的“周”指的是自然周，而非用药周期
证券之星 · 05-07 10:12
微芯生物：此处的“周”指的是自然周，而非用药周期
微芯生物：CS32582已完成I期临床，II期银屑病适应症正在筹备中
证券之星 · 05-07 10:12
微芯生物：CS32582已完成I期临床，II期银屑病适应症正在筹备中
微芯生物：公司今年未在AACR参展但密切关注全球肿瘤药早期研发进展
证券之星 · 05-07 10:12
微芯生物：公司今年未在AACR参展但密切关注全球肿瘤药早期研发进展
微芯生物：公司投资者热线电话保持畅通若偶尔未接通电话还望保持理解
证券之星 · 05-07 10:12
微芯生物：公司投资者热线电话保持畅通若偶尔未接通电话还望保持理解
微芯生物：公司设立了美国子公司，目前西奥罗尼正在美国开展临床试验
互动易 · 05-07 10:12
微芯生物：公司设立了美国子公司，目前西奥罗尼正在美国开展临床试验
微芯生物：西奥罗尼单药治疗三线及以上小细胞肺癌III期临床试验结果完成分析
证券之星 · 05-07 09:39
微芯生物：西奥罗尼单药治疗三线及以上小细胞肺癌III期临床试验结果完成分析
微芯生物：ASC22（恩沃利单抗）联合西达本胺疗法具有良好的耐受性
证券之星 · 05-07 09:39
微芯生物：ASC22（恩沃利单抗）联合西达本胺疗法具有良好的耐受性
微芯生物：定向增发的预案修订稿已于2025年4月26日公告披露，目前定增计划正在推进中
证券之星 · 05-07 09:39
微芯生物：定向增发的预案修订稿已于2025年4月26日公告披露，目前定增计划正在推进中
微芯生物：西达本胺2024年度毛利率93.27%，较上年度减少2.82个百分点
证券之星 · 05-07 09:39
微芯生物：西达本胺2024年度毛利率93.27%，较上年度减少2.82个百分点
微芯生物：糖尿病是可以治疗的疾病，但目前人类尚缺乏治愈糖尿病的有效药物
证券之星 · 05-07 09:36
微芯生物：糖尿病是可以治疗的疾病，但目前人类尚缺乏治愈糖尿病的有效药物
微芯生物：西格列他钠有效降低肝脏脂肪分数、减轻肝脏炎症和损伤
证券之星 · 05-07 09:36
微芯生物：西格列他钠有效降低肝脏脂肪分数、减轻肝脏炎症和损伤
微芯生物：公司已于2024年4月3日实施完成2024年股本回购计划
证券之星 · 05-07 09:36
微芯生物：公司已于2024年4月3日实施完成2024年股本回购计划
微芯生物：公司一季度的销售情况已按照法规格式的季度报告予以披露
证券之星 · 05-07 09:36
微芯生物：公司一季度的销售情况已按照法规格式的季度报告予以披露
微芯生物：公司BD部门正在积极探索基于国内数据申报海外上市的可能性
证券之星 · 05-07 09:36
微芯生物：公司BD部门正在积极探索基于国内数据申报海外上市的可能性
微芯生物05月07日遭主力抛售4.4万元
市场透视 · 05-07 07:20
微芯生物05月07日遭主力抛售4.4万元
加载更多
公司概况
公司名称：
深圳微芯生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2019-08-12
主营业务：
深圳微芯生物科技股份有限公司的主营业务为药物技术开发、相关成果商业应用，主要产品均为自主研究发现与开发的新分子实体且作用机制新颖的原创新药。公司获得2020中国医药工业信息中心颁发的“中国医药新锐创新力量”奖；2020年10月，公司获 得“2020中国化学制药行业成长型优秀企业品牌”与“2020中国化学制药行业抗肿瘤和免疫调节剂类优秀产品品牌”两个奖项。
发行价格：
20.43
{"stockData":{"symbol":"688321","market":"SH","secType":"STK","nameCN":"微芯生物","latestPrice":17.42,"timestamp":1746687600000,"preClose":17.16,"halted":0,"volume":3864497,"delay":0,"changeRate":0.0152,"floatShares":408000000,"shares":408000000,"eps":-0.2831,"marketStatus":"已收盘","change":0.26,"latestTime":"05-08 15:00:00","open":17.23,"high":17.7,"low":17.02,"amount":67534600,"amplitude":0.0396,"askPrice":17.46,"askSize":15,"bidPrice":17.42,"bidSize":151,"shortable":0,"etf":0,"ttmEps":-0.2831,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1746754200000},"marketStatusCode":5,"adr":0,"adjPreClose":17.16,"symbolType":"stock_kcb","openAndCloseTimeList":[[1746667800000,1746675000000],[1746680400000,1746687600000]],"highLimit":18.88,"lowLimit":15.44,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":407796477,"isCdr":false,"pbRate":4.94,"roa":"--","roe":"--","epsLYR":-0.2808,"committee":0.330211,"marketValue":7104000000,"turnoverRate":0.0095,"status":0,"afterMarket":{"amount":0,"volume":0,"close":17.42,"buyVolume":0,"sellVolume":0,"time":1746689638029,"indexStatus":"已收盘 05-08 15:30:00","preClose":17.16},"floatMarketCap":7104000000},"requestUrl":"/m/hq/s/688321","defaultTab":"news","newsList":[{"id":"2533286279","title":"2025年化学制药行业现状分析：优化工作设计","url":"https://stock-news.laohu8.com/highlight/detail?id=2533286279","media":"报告大厅","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533286279?lang=zh_cn&edition=full","pubTime":"2025-05-08 10:46","pubTimestamp":1746672385,"startTime":"0","endTime":"0","summary":"化学制药行业作业人员的 WMSDs 现状不容乐观，高发生率以及特定的发病部位和影响因素，给行业的职业健康管理带来了挑战。但通过对现状和影响因素的分析可知，2025 年化学制药行业在 WMSDs 防控方面将朝着强化培训、关注特定人群、优化工作设计等方向发展。行业内各方应积极行动起来，采取有效措施，降低作业人员发生 WMSDs 的风险，保障化学制药行业作业人员的身体健康，促进化学制药行业的可持续发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505081102469752a909&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505081102469752a909&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603229","688505","688321","688758","600488","688513","603676","BK0239","688076","603669","605116","688799","603168"],"gpt_icon":0},{"id":"2533622994","title":"【机构调研记录】凯石基金调研ST华通、微芯生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2533622994","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533622994?lang=zh_cn&edition=full","pubTime":"2025-05-08 08:04","pubTimestamp":1746662681,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及5月7日披露的机构调研信息，凯石基金近期对2家上市公司进行了调研，相关名单如下：1）ST华通 调研纪要：ST华通在游戏业务方面将重点关注长青游戏品类如SLG和三消类，注重创新与规模化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050800002915.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002602","BK0196","BK0077","BK0231","688321","BK0239","BK0094"],"gpt_icon":0},{"id":"2533945179","title":"【机构调研记录】先锋基金调研微芯生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2533945179","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533945179?lang=zh_cn&edition=full","pubTime":"2025-05-08 08:04","pubTimestamp":1746662677,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及5月7日披露的机构调研信息，先锋基金近期对1家上市公司进行了调研，相关名单如下：1）微芯生物 调研纪要：微芯生物介绍了西格列他钠在脂肪肝或MASH治疗中的应用，该药物已获批2型糖尿病适应症且纳入医保，有效改善胰岛素抵抗，在II期临床中观察到肝脏脂肪下降、改善纤维化、降低转氨酶、腰围缩小等多重获益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050800002909.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2533492198","title":"微芯生物：西格列他钠营收大增 研发管线持续推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2533492198","media":"财通证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533492198?lang=zh_cn&edition=full","pubTime":"2025-05-08 00:00","pubTimestamp":1746633600,"startTime":"0","endTime":"0","summary":"西格列他钠营业收入快速增长，西达本胺增长稳健：2024 年7 月西格列他钠联合二甲双胍治疗2 型糖尿病适应症获批后销量大增，2024 年实现营业收入1.40 亿元，同比增长231.76%。基于针对MASH 的Ⅱ期试验的良好疗效，公司将优先推动产品在2 型糖尿病合并MASH/MAFLD 患者人群中的应用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508145125a4764a7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508145125a4764a7b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688321"],"gpt_icon":0},{"id":"2533047376","title":"微芯生物：2024年西格列他钠（双洛平）糖尿病适应症成功原价续约医保谈判","url":"https://stock-news.laohu8.com/highlight/detail?id=2533047376","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533047376?lang=zh_cn&edition=full","pubTime":"2025-05-07 18:12","pubTimestamp":1746612754,"startTime":"0","endTime":"0","summary":"证券之星消息，微芯生物05月07日在投资者关系平台上答复投资者关心的问题。感谢您的关注与支持，微芯生物经过24年的发展，目前已完成2款原创新药6个适应症在中国大陆、中国台湾、日本上市销售，多款原创新药进入临床研发阶段。2024年西格列他钠（双洛平）糖尿病适应症成功原价续约医保谈判，脂肪肝II期临床结果于2024年美国肝病年会口头报告，相关市场推广工作积极推进中。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050700028952.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2533714604","title":"微芯生物：此处的“周”指的是自然周，而非用药周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2533714604","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533714604?lang=zh_cn&edition=full","pubTime":"2025-05-07 18:12","pubTimestamp":1746612744,"startTime":"0","endTime":"0","summary":"证券之星消息，微芯生物(688321)05月07日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，我们公司的西达本胺新适应症DLBCL，联合治疗达到完全缓解后单药维持治疗24周，这个24周是单纯的24周（一周7天）？还是24周期（一周期3周）？谢谢微芯生物回复：尊敬的投资者，您好。此处的“周”指的是自然周，而非用药周期。在实际用药过程中，医生可能会根据患者状况缩短或延长维持治疗周期，以便达到最大临床获益。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050700028929.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2533604789","title":"微芯生物：CS32582已完成I期临床，II期银屑病适应症正在筹备中","url":"https://stock-news.laohu8.com/highlight/detail?id=2533604789","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533604789?lang=zh_cn&edition=full","pubTime":"2025-05-07 18:12","pubTimestamp":1746612738,"startTime":"0","endTime":"0","summary":"证券之星消息，微芯生物(688321)05月07日在投资者关系平台上答复投资者关心的问题。投资者提问：微芯生物的TYK2抑制剂CS32582胶囊，在2023年10月31日，其治疗银屑病的临床试验申请获批，请问进展如何？微芯生物回复：尊敬的投资者，您好。CS32582已完成I期临床，II期银屑病适应症正在筹备中。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050700028915.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2533047916","title":"微芯生物：公司今年未在AACR参展但密切关注全球肿瘤药早期研发进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2533047916","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533047916?lang=zh_cn&edition=full","pubTime":"2025-05-07 18:12","pubTimestamp":1746612737,"startTime":"0","endTime":"0","summary":"证券之星消息，微芯生物(688321)05月07日在投资者关系平台上答复投资者关心的问题。投资者提问：第116届美国癌症研究协会（AACR）年会将于4月25日在芝加哥举行，请问公司有参与吗？对于生物医药研究领先的美国公司布局进展如何？微芯生物回复：尊敬的投资者，您好。公司今年未在AACR参展，但我们密切关注全球肿瘤药的早期研发进展。公司设立了美国子公司，目前西奥罗尼正在美国开展临床试验。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050700028910.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2533765604","title":"微芯生物：公司投资者热线电话保持畅通若偶尔未接通电话还望保持理解","url":"https://stock-news.laohu8.com/highlight/detail?id=2533765604","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533765604?lang=zh_cn&edition=full","pubTime":"2025-05-07 18:12","pubTimestamp":1746612728,"startTime":"0","endTime":"0","summary":"证券之星消息，微芯生物(688321)05月07日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，075526952070这个电话一直打不通，这个对公司形象损害有点大啊微芯生物回复：尊敬的投资者，您好。公司投资者热线电话保持畅通，若偶尔未接通电话，还望您保持理解。公司投资者热线电话有来电显示并对每日来电都有登记记录，我们发现漏接电话后，事后会打回去沟通，望您的电话保持畅通。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050700028897.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2533988661","title":"微芯生物：公司设立了美国子公司，目前西奥罗尼正在美国开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2533988661","media":"互动易","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533988661?lang=zh_cn&edition=full","pubTime":"2025-05-07 18:12","pubTimestamp":1746612721,"startTime":"0","endTime":"0","summary":"有投资者向微芯生物提问， 第116届美国癌症研究协会（AACR）年会将于4月25日在芝加哥举行，请问公司有参与吗？对于生物医药研究领先的美国公司布局进展如何？公司回答表示，尊敬的投资者，您好。公司今年未在AACR参展，但我们密切关注全球肿瘤药的早期研发进展。公司设立了美国子公司，目前西奥罗尼正在美国开展临床试验。感谢您的关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507181955a6d634a7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507181955a6d634a7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2533608009","title":"微芯生物：西奥罗尼单药治疗三线及以上小细胞肺癌III期临床试验结果完成分析","url":"https://stock-news.laohu8.com/highlight/detail?id=2533608009","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533608009?lang=zh_cn&edition=full","pubTime":"2025-05-07 17:39","pubTimestamp":1746610767,"startTime":"0","endTime":"0","summary":"西奥罗尼单药治疗三线及以上小细胞肺癌III期临床试验结果完成分析，独立评审委员会评估结果显示：在经过广泛抗肿瘤免疫治疗后的总体人群中，西奥罗尼组与安慰剂组相比中位无进展生存期显著延长，降低疾病进展风险70%以上。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050700027025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","BK1583","688321","BK1141","03347","BK0239"],"gpt_icon":0},{"id":"2533060807","title":"微芯生物：ASC22（恩沃利单抗）联合西达本胺疗法具有良好的耐受性","url":"https://stock-news.laohu8.com/highlight/detail?id=2533060807","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533060807?lang=zh_cn&edition=full","pubTime":"2025-05-07 17:39","pubTimestamp":1746610767,"startTime":"0","endTime":"0","summary":"一项由上海市公共卫生临床中心主导的II期试验显示，ASC22联合西达本胺疗法具有良好的耐受性，且有效地激活了潜伏的HIV病毒库。受试者第8周和第12周的细胞相关HIVRNA与基线水平相比显著增加，平均增幅分别为4.27倍和3.41倍。HIV细胞相关RNA与总DNA的比值也呈现相同的趋势。该疗法需展开进一步研究，相关结果已于第12届国际艾滋病协会HIV科学会议上公布。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050700027023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2533608024","title":"微芯生物：定向增发的预案修订稿已于2025年4月26日公告披露，目前定增计划正在推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2533608024","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533608024?lang=zh_cn&edition=full","pubTime":"2025-05-07 17:39","pubTimestamp":1746610755,"startTime":"0","endTime":"0","summary":"证券之星消息，微芯生物(688321)05月07日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贾先平董事长，公司股价现低于发行价，定增会继续推进吗？微芯生物回复：尊敬的投资者，您好！公司董事长为鲁先平博士，相互尊重是沟通交流的基础，谢谢您！定向增发的预案修订稿已于2025年4月26日公告披露，目前定增计划正在推进中。公司的定增发行价会按照相关法律法规和市场情况而确定。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050700027017.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2533608747","title":"微芯生物：西达本胺2024年度毛利率93.27%，较上年度减少2.82个百分点","url":"https://stock-news.laohu8.com/highlight/detail?id=2533608747","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533608747?lang=zh_cn&edition=full","pubTime":"2025-05-07 17:39","pubTimestamp":1746610751,"startTime":"0","endTime":"0","summary":"证券之星消息，微芯生物05月07日在投资者关系平台上答复投资者关心的问题。西达本胺2024年度毛利率93.27%，较上年度减少2.82个百分点，生产成本的合理增加对整体利润的响影较小。西达本胺的成本构成中，2024年直接人工所用金额同比增长32.87%，直接材料同比增长49.49%，制造费用同比增长141.77%。目前西格列他钠相关适应症的正式临床试验均已完成，产品已商业化，因此不再属于“临床阶段的研发管线”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050700027014.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2533608027","title":"微芯生物：糖尿病是可以治疗的疾病，但目前人类尚缺乏治愈糖尿病的有效药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2533608027","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533608027?lang=zh_cn&edition=full","pubTime":"2025-05-07 17:36","pubTimestamp":1746610609,"startTime":"0","endTime":"0","summary":"证券之星消息，微芯生物(688321)05月07日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，公司说西格列他钠（双洛平）可有效控制血糖、治疗糖尿病。请问糖尿病不是没法治疗吗？请问国内外哪些糖尿病药作用机理和双洛平类似？微芯生物回复：尊敬的投资者，您好。糖尿病是可以治疗的疾病，但目前人类尚缺乏治愈糖尿病的有效药物。目前全球尚无同类PPAR全激动剂上市销售，但有个别同机制药物正在临床试验阶段。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050700026952.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2533608046","title":"微芯生物：西格列他钠有效降低肝脏脂肪分数、减轻肝脏炎症和损伤","url":"https://stock-news.laohu8.com/highlight/detail?id=2533608046","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533608046?lang=zh_cn&edition=full","pubTime":"2025-05-07 17:36","pubTimestamp":1746610608,"startTime":"0","endTime":"0","summary":"结果显示西格列他钠有效降低肝脏脂肪分数、减轻肝脏炎症和损伤，并有改善纤维化的趋势，且呈剂量依赖性效应，安全性和耐受良好。西格列他钠已获批2型糖尿病适应症，积累了丰富真实用药经验，且超过一半的糖尿病患者同时患有代谢相关脂肪性肝病，临床就诊的MASH患者大部分已合并糖尿病。同时，公司将持续携手研究者完善西格列他钠治疗脂肪肝全病程的证据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050700026953.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2533080746","title":"微芯生物：公司已于2024年4月3日实施完成2024年股本回购计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2533080746","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533080746?lang=zh_cn&edition=full","pubTime":"2025-05-07 17:36","pubTimestamp":1746610592,"startTime":"0","endTime":"0","summary":"证券之星消息，微芯生物05月07日在投资者关系平台上答复投资者关心的问题。公司始终高度重视全体股东权益保护工作。公司已于2024年4月3日实施完成2024年股本回购计划。此次公司以集中竞价交易方式累计回购公司股份74.8388万股，占公司总股本的0.18%，支付的资金总额为人民币14995513.61元。2024年5月31日，该部分回购股份以及公司于2021年回购尚余的274.2600万股，合计共349.0988万股均已注销。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050700026936.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2533608017","title":"微芯生物：公司一季度的销售情况已按照法规格式的季度报告予以披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2533608017","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533608017?lang=zh_cn&edition=full","pubTime":"2025-05-07 17:36","pubTimestamp":1746610591,"startTime":"0","endTime":"0","summary":"证券之星消息，微芯生物05月07日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司2025年一季度双洛平销售额是多少？公司一季度的销售情况已按照法规格式的季度报告予以披露，当然您提出的意见我们也能充分的理解，我们会在今后的定期报告后及时以一图简报等形式，更多维度的把公司经营情况与业绩做好呈现，利于广大投资者理解与判断。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050700026935.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2533608025","title":"微芯生物：公司BD部门正在积极探索基于国内数据申报海外上市的可能性","url":"https://stock-news.laohu8.com/highlight/detail?id=2533608025","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533608025?lang=zh_cn&edition=full","pubTime":"2025-05-07 17:36","pubTimestamp":1746610569,"startTime":"0","endTime":"0","summary":"西格列他钠的开发时间较早，当时国内临床前研究的执行规范与海外主要市场现行的要求不太一致，部分历史数据都无法直接采用。公司BD部门正在积极探索基于国内数据申报海外上市的可能性，通过与部分发展中国家当地企业的沟通，深入调研当地市场潜力、注册路径及商业化条件，目前在与潜在合作企业就项目的落地方式进行商讨。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050700026917.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2533671983","title":"微芯生物05月07日遭主力抛售4.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533671983","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533671983?lang=zh_cn&edition=full","pubTime":"2025-05-07 15:20","pubTimestamp":1746602432,"startTime":"0","endTime":"0","summary":"05月07日, 微芯生物股价跌1.55%，报收17.16元，成交金额5175.1万元，换手率0.73%，振幅3.90%，量比0.75。微芯生物今日主力资金净流出4.4万元，连续5日净流出，上一交易日主力净流出1011.5万元。该股近5个交易日上涨1.66%，主力资金累计净流出1809.2万元；近20日主力资金累计净流出4519.7万元，其中净流出天数为15日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507164826a6d61867&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507164826a6d61867&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688321","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1746694282035,"stockEarnings":[{"period":"1week","weight":0.0012},{"period":"1month","weight":0.1282},{"period":"3month","weight":-0.0545},{"period":"6month","weight":-0.2744},{"period":"1year","weight":-0.2729},{"period":"ytd","weight":-0.0764}],"compareEarnings":[{"period":"1week","weight":0.0194},{"period":"1month","weight":0.0795},{"period":"3month","weight":0.022},{"period":"6month","weight":-0.0318},{"period":"1year","weight":0.0619},{"period":"ytd","weight":-0.0027}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳微芯生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"17684人(较上一季度减少1.85%)","perCapita":"23060股","listingDate":"2019-08-12","address":"广东省深圳市南山区西丽街道曙光社区智谷产业园B栋21F-24F","registeredCapital":"40779万元","survey":" 深圳微芯生物科技股份有限公司的主营业务为药物技术开发、相关成果商业应用，主要产品均为自主研究发现与开发的新分子实体且作用机制新颖的原创新药。公司获得2020中国医药工业信息中心颁发的“中国医药新锐创新力量”奖；2020年10月，公司获 得“2020中国化学制药行业成长型优秀企业品牌”与“2020中国化学制药行业抗肿瘤和免疫调节剂类优秀产品品牌”两个奖项。","listedPrice":20.43},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.4","shortVersion":"4.33.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"微芯生物(688321)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供微芯生物(688321)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"微芯生物,688321,微芯生物股票,微芯生物股票老虎,微芯生物股票老虎国际,微芯生物行情,微芯生物股票行情,微芯生物股价,微芯生物股市,微芯生物股票价格,微芯生物股票交易,微芯生物股票购买,微芯生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"微芯生物(688321)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供微芯生物(688321)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}